Agios Andreas in Kavala offers breathtaking views, traditional Greek architecture, authentic local culture, charming streets, and serene landscapes that make it a must-visit destination for travelers ...

Shares of Agios Pharmaceuticals (AGIO.O), jumped nearly 16% after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder. The drug, ...

Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO.O), opens new tab jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the ...

Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia ...

The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a ...

Agios expects Aqvesme to be available in late January 2026 following full REMS implementation. H.C. Wainwright updated its model to reflect a first-quarter 2026 commercial launch and increased the ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. The trial was designed with two primary endpoints, and it hit ...

Nov 19 (Reuters) - Agios Pharmaceuticals (AGIO.O), opens new tab said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but ...

Shares of Agios Pharmaceuticals (AGIO) plunged ~45% in the premarket on Wednesday after the biotech announced a mixed outcome from a late-stage trial for its lead asset mitapivat in sickle cell ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...